There remain challenges to the implementation of such a system, particularly with regard to different normal biodistribution patterns and the variable impact of tumor burden among the available SSTR- and PSMA-PET radiopharmaceuticals, which should be addressed in future studies. Here, FOLH1 is linked to neoplasm.